Literature DB >> 8241604

What constitutes evidence for drug efficacy in osteoporosis?

J A Kanis1.   

Abstract

Entities:  

Mesh：

Year:  1993        PMID： 8241604     DOI： 10.2165/00002512-199303050-00001

Source DB:  PubMed          Journal:  Drugs Aging        ISSN： 1170-229X            Impact factor:   3.923


× No keyword cloud information.
  46 in total

1.  Bone-density measurement.

Authors:  J C Stevenson; J A Kanis; C Christiansen
Journal:  Lancet       Date:  1992-02-08       Impact factor: 79.321

2.  Bone hypertrophy and trabecular generation in Paget's disease and in fluoride-treated osteoporosis.

Authors:  J E Aaron; M C de Vernejoul; J A Kanis
Journal:  Bone Miner       Date:  1992-06

3.  Bone density screening for osteoporosis.

Authors:  B E Nordin; A G Need; B E Chatterton; M Horowitz; D B Cleghorn
Journal:  Lancet       Date:  1990-11-24       Impact factor: 79.321

4.  Epidemiology of vertebral fractures in women.

Authors:  L J Melton; S H Kan; M A Frye; H W Wahner; W M O'Fallon; B L Riggs
Journal:  Am J Epidemiol       Date:  1989-05       Impact factor: 4.897

5.  Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.

Authors:  B L Riggs; S F Hodgson; W M O'Fallon; E Y Chao; H W Wahner; J M Muhs; S L Cedel; L J Melton
Journal:  N Engl J Med       Date:  1990-03-22       Impact factor: 91.245

6.  A comparison of single and multi-site BMC measurements for assessment of spine fracture probability.

Authors:  R D Wasnich; P D Ross; J W Davis; J M Vogel
Journal:  J Nucl Med       Date:  1989-07       Impact factor: 10.057

Review 7.  Epidemiology of vertebral osteoporosis.

Authors:  J A Kanis; E V McCloskey
Journal:  Bone       Date:  1992       Impact factor: 4.398

8.  Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group.

Authors:  S R Cummings; D M Black; M C Nevitt; W Browner; J Cauley; K Ensrud; H K Genant; L Palermo; J Scott; T M Vogt
Journal:  Lancet       Date:  1993-01-09       Impact factor: 79.321

9.  Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture.

Authors:  J A Kanis; O Johnell; B Gullberg; E Allander; G Dilşen; C Gennari; A A Lopes Vaz; G P Lyritis; G Mazzuoli; L Miravet
Journal:  BMJ       Date:  1992-11-07

10.  Reduced occurrence of vertebral crush fractures in senile osteoporosis treated with 1 alpha (OH)-vitamin D3.

Authors:  H Orimo; M Shiraki; T Hayashi; T Nakamura
Journal:  Bone Miner       Date:  1987-10
View more
  7 in total

Review 1.  Estradiol and dydrogesterone. A review of their combined use as hormone replacement therapy in postmenopausal women.

Authors:  R H Foster; J A Balfour
Journal:  Drugs Aging       Date:  1997-10       Impact factor: 3.923

Review 2.  Alendronate: an update of its use in osteoporosis.

Authors:  M Sharpe; S Noble; C M Spencer
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  A high dietary calcium intake is needed for a positive effect on bone density in Swedish postmenopausal women.

Authors:  K Michaëlsson; R Bergström; L Holmberg; H Mallmin; A Wolk; S Ljunghall
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

4.  Events per person year. A decrease in multiple events may be missed.

Authors:  J A Kanis; E V McCloskey
Journal:  BMJ       Date:  1995-06-03

Review 5.  Alendronate. A review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis.

Authors:  W Jeal; L B Barradell; D McTavish
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

Review 6.  Rationale for the use of alendronate in osteoporosis.

Authors:  J A Kanis; B J Gertz; F Singer; S Ortolani
Journal:  Osteoporos Int       Date:  1995-01       Impact factor: 4.507

Review 7.  Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  C J Dunn; A Fitton; E M Sorkin
Journal:  Drugs Aging       Date:  1994-12       Impact factor: 3.923
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.